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Objective: To evaluate nested PCR for Toxoplasma gondii (TOX), JC virus (JCV) and Epstein-Barr virus (EBV) for 
diagnosis of toxoplasmic encephalitis (TE), progressive multifocal leukencephalopathy (PML) and primary central 
nervous system lymphoma (PCL). 
Methods: A prospective study encompassed 26 HIV-I-infected individuals presenting with focal neurologic signs and 
symptoms. Nested PCR was performed on both supernatants and pellets of centrifuged cerebrospinal fluid (CSF), on 
plasma and on white blood cells (WBCs). For a retrospective study, stored CSF supernatants were available from an 
additional 27 HIV-1-infected patients with TE, PML, and PCL. 
Results: TE, PML or PCL was diagnosed in 13 of 26 patients in the prospective group. Plasma and WBC analysis by 
PCR was not informative except in one case of TE. TOX and JCV were detected by PCR in the CSF pellets of four of five 
patients with TE, and of four of five patients with PML, respectively, but in no other cases. EBV was detected not only 
in three of three cases of PCL, but also in six patients suffering from other conditions. PCR on the CSF supernatants was 
less sensitive for all three etiologies. These results correlated with those of the retrospective PCR analysis, for which 
only stored CSF supernatants were available, revealing sensitivities of 33%, 50% and 66% for TE, PML and PCL, 
respectively, but specificities of 100%. 
Conclusions: In the clinical routine, TOX and JCV PCR on centrifuged CSF pellets can be recommended to obtain an 
early diagnosis of TE and PML. Under these conditions, EBV PCR helps to  exclude PCL as a cause of FBLs, as it is highly 
sensitive, but not specific, for PCI- in  HIV-I-infected individuals. 
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I NTRO D U CTlON 
In  AIDS patients with focal brain lesions (FBLs), 
toxoplasmic encephalitis (TE), primary central nervous 
system lymphoma (PCL) and progressive multifocal 
leukoencephalopathy (PML) are considered to be the 
main differential diagnoses. PML, PCL and most 
cases of TE arise as consequences of immunologically 
uncontrolled latent infections with JC polyoma virus 
(JCV), Epstein-Barr virus (EBV) and Toxoplasmn gondii 
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(TOX), respectively [l-41. In Switzerland, TE, PML 
and PCL accounted for about 3.5% of the 2600 
diagnoses recorded by the Swiss HIV Cohort Study in 
1995 [j]. 
Typical but non-specific radiologic features for each 
condition have been noted on computed tomography 
(CT) arid magnetic resonance imaging (MRI) scans [6]. 
TOX serology is diagnostically not helpful, except in 
identi@ing seropositive individuals facing an increased 
risk for TE [7] .  The definitive diagnosis of FBLs 
may be sought by stereotactic brain biopsy. However, 
this procedure is invasive and has a sensitivity of 
only 80-90%, because of necrotic biopsy samples [8]. 
Currently. an early empirical therapy trial with anti- 
tosoplasma drugs is recommended in HIV-1 -infected 
patients with FBL. Clinical and radiologic response is 
taken as evidence for TE. Only after treatment failure 
is a brain biopsy performed [7]. 
Recently, the polymerase chain reaction (PCR) 
has been used to detect TOX, EBV and JCV genonies 
in the cerebrospinal fluid (CSF) of clinically or histo- 
logically defined cases of TE, PCL and PML (reviewed 
in [(I]). For TOX and JCV PCR,  a high specificity 
(>90@%) h,is been described, but the sensitivity varied 
widely between 0% and 100% [lo-1 31. I n  contrast, 
EBV PCR as a marker for PCL in AIDS patients has 
been reported to be both sensitive (83-100%) and 
specific (94-100%1) [ 12,14-161. Given the diagnostic 
potential of I’CK in a clinical situation [Y,17], we 
prospectively evaluated the role of nested PCR in HIV- 
1-infected patients with focal neurologic signs and 
symptoms, and compared the results with the clinically 
or histologically defined outcome. We analyzed the 
value of CSF centrifugation, 3s well as the detection of 
TOX, EllV and JCV in the peripheral blood. Further- 
more. stored CSF saniples from 27 patients with TE, 
PML and PCL were analyzed retrospectively. Our 
results support the view that TOX and JCV PCR on 
centrifugation-enriched CSF are valuable tools i n  the 
clinical situation, but the low positive predictive value 
of EHV PCK limits its diagnostic value for 1’CL in 
HIV-1 -infected patients. 
MATERIALS AND METHODS 
Patients and diagnoses 
Twentysix HIV-1-infected patients presenting with 
focal neurologic signs and symptoms were entered into 
the prospective study from June 1995 until December 
1996. CT and MRI scans were obtained on all patients. 
None showed evidence for increased intracranial 
pretsure which might have precluded lumbar puncture. 
CSF and EDTA blood was then obtained with in- 
formed consent. Data were collected at  the time of 
initial presentation and at  follow-up 1, 3 and, in some 
cases, 6 months after luiiibar puncture, with the use of 
standardized study fornis to document the signs, 
symptoms, therapy, diagnostic procedures (including 
radiologic imaging) and clinical course. Examination 
by MRI or C T  scans confirmed FBLs in  21 of the 26 
patients. For 21 patients with FBLs, TE was diagnosed 
by histopatholorn (definitive, I I  = 1) or by contrast- 
enhancing lesions on CT or MRI scans and clinical arid 
radiologic improvement following adequate antitoxo- 
plasnia therapy within 2 weeks (presumptive, n= 4) 
which clearly precluded, on ethical grounds, further 
histologic confirmation by biopsy. For 14 patients 
with FBLs and failure of antitoxoplasma therapy, the 
diagnoses were made (1) by histopathology in four cases 
(PML, n=2;  PCL. n=2) .  (2) by the identification of 
another infectious etioloLy in the CSF in three catet 
(Mycobactevicrrn auirrni complex by culture identified 
together with cytoniegalovirus, / I  = 1; cytoinegalovirus 
encephalitis arid retinitis, I I  = 2). (3) by the radiologic 
findings together with the clinical course, laborator)- 
and neurophysiologic work-up in seven cases indicating 
presumptive PML (n=3; compatible lesions on C T  or 
MRI scan without response to TOX therapy, and with- 
out evidence for lymphoma arid HIV encephalopathy), 
presumptive PCL ( t i = l ;  compatible FBLs on C T  or 
MRI scan without response to TOX therapy in the 
absence of lyniphonia outside the brain), ischemic 
vasculitis (n=2),  and heinatonia ( n = l ) .  For two patients 
with unknown focal lesions on MKI upon presen- 
tation, spontaneous resolution without antitoxoplasnia 
therapy was observed. Five patients with focal neurologic 
signs and symptoms, but lacking radiologic evidence 
for FBLs, were diagnosed as having disseminated non- 
Hodglun’s lymphoma by histology of peripheral biopsies 
( n = l ) ,  myeloradiculitidserum sickness (n=l) by CSF 
and serum analysis, HIV encephalopathy by diffuse 
white matter lesions on CT scans with other etiologiec 
being excluded ( t i z l ) ,  peripheral neuropathy ( n = l ) .  
arid neuroborreliosis with intrathecal production of 
Bovrelin buqdofr-fevi-specific antibodies ( I / =  1).  
The retrospective analysis consisted of stored CSF 
supernatants (-20°C) of 27 different patients with 
focal neurologic abnormalities documented by the 
Swiss HIV-1 Cohort Study until 199.5. 111 this group. 
TE, PCL or PML WAS diagnosed according to the 
following criteria: definitive TE ( t i  =4), I’CL ( n  =9), or 
PML (n=8)  by histology in 23 cases; the ren~iining six 
cases being presuniptive TE  ( t i  =2) and presumptive 
PML (n=4) as defined above. 
DNA preparation 
For the projpectlve ttudy. CSF wa\ kept dt 4°C fior not 
longer than 24 h. One mdhhter of CSF was centrifuged 
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(15 000 rev/min, 30 min, in an Eppendorf table-top 
centrifuge), and the supernatants were removed from 
the top, leaving 200 pL of the CSF to resuspend any 
pelleted material (CSF pellets). This enriched for cells, 
protozoa and cell-associated virus, while unsedimented 
material, e.g. free virus, was recovered from the 200- 
pL CSF supernatants used for resuspension. EDTA- 
blood cells were pelleted by centrifugation and the red 
blood cells lysed in 10 mL 0.84 M NH4Cl (4”C, 30 
min). The remaining white blood cells (WBCs) were 
wahed, resuspended in phosphate-buffered saline 
(PBS), and stored at -20OC until extraction. CSF 
supernatants of the retrospective analysis were kept 
frozen at -20OC until DNA extraction. CSF pellets, 
CSF supernatants, plasma and WBCs were extracted 
as 200-pL volumes using protease digestion and spin 
columns of a commercial kit procedure (QIAmp, 
QIAGEN, Basel, Switzerland). The presence of 
amplifiable DNA in the CSF and blood preparations 
was confirmed by 40 cycles of P C R  (9S°C, 5O0C, 
72”C, 30 s each, followed by 15 min of 72°C) with 
primers specific for the human TNF-a  gene 5’- 
TGAAGCCGTGGGTCAGTATG-3’ and 5’-TCAG- 
CAAGGACAGCAGAGGA-3’ (H.P. Senn, personal 
communication). 
Nested PCR 
All steps of the P C R  analysis were performed at the 
Molecular Diagnostic Laboratory of the Institute for 
Medical Microbiology of the University of Basel. 
Precautions to avoid carryover contamination were 
applied routinely at  every step, including aerosol- 
barrier pipette tips, uracyl-N-glycosylase digestion and 
dTTP replacement with dUTP in all amplification 
reactions. The specimens for analysis proceeded in one 
direction through distinct areas for preparation, 
extraction, amplification, detect:ion and disposal. 
Amplification was performed after preincubation 
(37OC, 10 min) by use of a Perkin-Elmer GeneAmp 
PCR System 9600. For each P C R  analysis, 5 pL of the 
control or the patient DNA preparation was used. The 
outer P C R  master mix (15.‘75 pL per tube) was 
prepared immediately before the P C R  was started and 
consisted of 5 pL ~ 1 0  PCR I1 buffer (Perkin-Elmer, 
Rotkreuz, Switzerland), 5 pL 25 mM MgC12, 0.2 pL of 
25 mM dATP, dGTP and dCTP, 0.1 pL of 100 mM 
dUTP (Boehringer Mannheim, Germany), 2.5 pL of 
8 pM of each primer, 0.2 pL of Ei U AmpliTaq (Perkin- 
Elmer), and 0.25 pL of uracyl-PJ-glycosylase (1 U/pL; 
Gibco, Basel, Switzerland). Autoclaved double-distilled 
water was added up to a total volume of 50 pL. For the 
inner PCR,  3 pL of the outer reaction was transferred. 
The inner P C R  master mix was prepared (15.5 pL per 
tube, total volume 50 pL) as described above, except 
that the inner primers were used, and the uracyl-N- 
glycosylase was omitted. Ten-microliter aliquots of the 
product were separated on 2.2% agarose electrophoresis 
gels, and stained with ethidium bromide. 
TOX DNA was detected by amplification of the 
35-fold repeated B1 gene [IS], using 40 cycles for the 
outer and the inner reactions (94OC, 5OoC, 72°C for 
30 s each, followed by 72OC for 15 min). The outer 
primer pair was 5’-GGAACTGCATCCGTTCAT- 
GAG-3’ and 5’-TCTTTAAAGCGTTCGTGGTCA- 
3’ and the inner primer pair 5’-TGTGGGAATG- 
AAAGAGACGCTA-3’ and 5’-CGACCAATCTG 
CGAATACACC-3’, generating an amplicon of 134 bp 
(unpublished in-house method). The detection of EBV 
DNA was performed as described by Cinque et a1 
[I41 (amplicon size of 209 bp). For the detection of 
JCV genome we used a semi-nested P C R  format 
based on Arthur et a1 [19], with the outer primers 
5’-AAGTCTTTAGGGTCTTCTAC-3’ and 5’- 
GTGCCAACCTATGGAACAGA-3’, and the inner 
primers 5’-AAGTCTTTAGGGTCTTCTAC-3’ and 
5’-GAATCCTGGTGGAATACA-3’ (94”C, 30 s; 
50”C, 45 s; 72”C, 60 s; 30 cycles; amplicon size of 
146 bp). The JCV protocol, the primers and the 
positive plasmid control were obtained from M. Renz 
(Amplimun, Madulain, Switzerland). The threshold 
of detection was determined as three positive B95-8 
cells (ATCC CRL 1612) for EBV PCR,  and as three 
plasmid copies for the TOX and JCV PCR. 
The standard P C R  protocol in our laboratory 
for each diagnostic run consisted of (1) one external 
negative control (1 pg of human peripheral blood 
leukocyte (PBL) DNA); (2) two external positive 
controls in 250 ng of herring sperm DNA (Fluka) 
spiked with a high and a low positive control; and (3) 
five reactions for each patient sample, i.e. duplicate runs 
of the patient sample flanked by two negative carryover 
controls (double-distilled water) as well as one reaction 
of the patient sample spiked with the high positive 
control target. When the results of the patient duplicates 
were discrepant, the specimen was re-analyzed in 
independent quadruplicates. Diluted DNA preparations 
from biopsy preparations of histologically confirmed 
cases of TE, PML and PCL served as positive reference 
controls. TOX RH tachyzoites grown in mouse ascites 
as positive controls were provided by P. Erb. For 
monitoring of the threshold of detection, the external 
high and low positive controls consisted of 15 and 
three plasmid copies for TOX PCR,  of seven and 
three infected B95-8 cells for EBV PCR,  and of 15 and 
seven plasmid copies for JCV PCR.  The repro- 
ducibility of the P C R  was calculated as the percentage 
of concordant results over the number of reactions 
performed. 
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RESULTS 
Prospective study 
Table 1 shows the characteristics of the 26 HIV-1- 
infected individuals with focal neurologic signs and 
symptoms. With a mean age of 36 i-10 years and about 
27% females, the age/gender ratio corresponded to the 
one currently described in Switzerland by the Swiss 
HIV-1 Cohort Study (33k8 years; 26% females)[S]. 
In 21 of 26 patients, FBLs with or without coiitrast 
enhancement were detected on C T  ( 1 1 ~ 2 )  or MRI 
scans (n=19), 13 of them with two or more foci. Of 
note is the fact that six of 21 patients with FBLs died 
within SO days after inclusion in the study. 
The final diagnoses of the prospective study shown 
in Table 2 were obtained as described above. The results 
of the PCK analyse4 of CSF pellets, CSF supernatants, 
plasma and WBCs are shown in Table 3. A repre- 
Table 1 Characteristics of thc prospective study population 
Patients n i th  
focal brain lcsions All pdticnts 
1 )e~crlption (total 21) (total 26) 
Frill&\ 
Male\ 
Agc (ycan) 
C : l N  ccll coullt/pL 
C l X  Stage (3 
Ki,k 
lntrnvenous drug iirer 
Homoscxual contacts 
Hctero\exual cont<icts 
Not specified 
?;,xiiplasma seropoii rive 
.i\ntiprotozo.zl prophylaxis 
Symptomatic day\ before spinal tap 
I'ntients deceased 
< 100 ddVS 
<.iO days 
7 (33%) 
14 (66%) 
37?10 (34124-71)' 
13 (62%) 
104?163 (38/10-605)' 
8 (38%) 
8 (39%) 
3 (14%)) 
2 (1 0%) 
13 (62%) 
27-t 23 (22  I - lo l l )  ' 
12 (5796) 
11 (52%) 
9 (43%) 
6 (29%) 
7 (27'%) 
19 (73%) 
,365 1 0  (31124-71)" 
I25 -t 1 69 (39 ' 10-605) " 
I 4  (54%) 
1 I! (38'%) 
10 rI8%1) 
3 [ 1 ?'%I) 
3 [ 12%) 
14 (54"b) 
25?21 (21 I-1011)' 
12 ( 4 W )  
Ill (38%)) 
7 (27%) 
1.5 (58%) 
~~~~ 
" M e m ?  standard deviation (niedian/range). 
Table 2 Diagnosir and PCR results in cerebrospinal fluid pellet of the prospective study group 
I'atien t TOX EBV 1c:v 
K ' l ~ i l o l o ~  ' I>iagno\is number PCIL I'CK PCIL 
Focal brain lesioiic '~bx1&rr71a eiicephalitir 
Progres\i\-e niultifocal Icukoencephalopath) 
Primary central nrrvouf system lymphoma 
Cytomegalovirus 
.\1. nvitrrii coniplcx/rytoiiiegalovirus 
Isrhemlc varculltls 
Hematoma 
Unkiio\\-ii, spontanrous rrcovery 
No  focal bi-am leciori, Mriiingitis (neuroborrelioiisj 
Lhseminatcd non-Hodgkinh lymplion~a 
HIV encephahtii 
Myeloradiculitis/serum sickness 
Peripheral iieuropathy 
All patient< 
> 
5 
3 
2 
1 
2 
1 
21 
7 - 
26 
1 1 1 1  
I!/ 1 
!)/ 1 
0 / 1  
4/2.i 
"A\ defined by computed tomography or magnetic reionance imaging. 
"Amplification inhibited. 
TOX, %opln.w~o yorldii; EBV. Epstciil-Ual I- x-irus: JCV, JC; pOlyorJld viru). 
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sentative P C R  analysis for three patients is shown in 
Figure 1. With a high assay reproducibility, 14 of the 
26 CSF pellets were found to be PCR positive for 
either TOX, EBV or JCV. In one patient without FBLs, 
the negative P C R  result for the three agents could not 
be scored because amplification of the ‘spiked’ target 
DNA was inhibited. CMV PCR. data were available for 
15 CSF preparations, three of which were positive (data 
not shown). In four CSF preparations of patients with 
FBLs, a positive EBV signal was found in addition to a 
first P C R  signal (one TOX, two JCV, one CMV). 
Based on the diagnoses and the P C R  results listed in 
Table 2, the sensitivity, specificity and positive and 
negative predictive values for P C R  results in the CSF 
pellet preparations were calculated (Table 3) .  
A positive TOX P C R  result in the CSF pellets was 
found in four of five patients with TE (CD4 cell count 
24 f  13, mean rfr SD). All were TOX seropositive, but 
only three were taking TOX prophylaxis. The patient 
with TE with a negative TOX PCR result had been on 
antitoxoplasma therapy for 3 weeks at the time of CSF 
sampling. N o  TOX P C R  signal was detected in the 
CSF pellets of the 16 FBL patients not responding 
to antitoxoplasma treatment, or in those of the five 
patients laclung radiologic evidence of FBLs. Of note 
is the fact that TOX and EBV P C R  signals were 
detected together in the CSF of one patient who could 
not take antitoxoplasmic therapy due to adverse effects, 
and for whom autopsy confirmed TE but not PCL. 
Positive JCV P C R  signals were found in four of 
five cases of PML (mean CD4 cell count/pL 96+81), 
all of which belonged radiologically in the group of 16 
FBL patients not responding to antitoxoplasma therapy. 
No JCV genomes were detected in the five cases with 
TE and the five patients lacking FBLs. 
A positive EBV PCR result was found in seven of 
16 patients with FBLs who did not respond to 
antitoxoplasma therapy. However, the diagnosis of PCL 
could be made in only three cases. The remaining four 
had PML ( n = 2 ) ,  CMV encephalitis following CMV 
retinitis ( n = l ) ,  and ischemic vasculitis (n =I).  Among 
the five patients without radiologic evidence of FBLs, 
a positive EBV P C R  was found in one case of neuro- 
borreliosis with significant intrathecal production of 
B. btrrgdorferi-specific antibodies. No PCL was diag- 
nosed in any of the nine FBL patients without EBV 
PCR signals. Therefore, the negative predictive value 
of EBV PCR was found to be loo%, while the positive 
predictive value was as low as 38%. 
The P C R  analysis of the CSF supernatants revealed 
a reduced sensitivity, missing nine of the 14 positive 
P C R  signals found in the CSF pellets (Table 3) ,  in- 
cluding two of three cases of PCL. In the WBC 
preparation, only one of the five cases of TE could be 
diagnosed by TOX PCR,  suggesting a disseminated 
infection. No JCV genomes were detected in these 
WBC preparations, but 16 (84%) were positive for 
EBV. PCR on plasma preparations was not useful for 
TE or PCL (Table 3 ) .  
Retrospective PCR analysis 
For the retrospective analysis, 27 CSF samples were 
available from patients with the diagnosis of TE, PCL 
or PML as documented in the Swiss HIV-1 Cohort 
Table 3 PCR results in different specimens of the prospective study population 
Sensitivity Specificity PPV NPV REP 
P C R  Material Result a (“A) (“A) (%) (“A) (“A) 
TOX CSF pellet 
CSF supb 
Plasma 
WBC 
EBV CSF pellet 
CSF sup’ 
Plasma 
wnc 
JCV CSF pellet 
CSF suph 
Plasma 
wnc 
4/25 80 100 100 94 97 
3/4 
0/1Y 
1/19 
9/25 100 72 38 100 97 
0/6 
2/19 
16/19 
4/25 80 100 100 94 99 
2/4 
Not done 
0/19 
Sensitivity specificity, positive predictive value (PPV) and negative predictive value (NPV) of the P C R  in the CSF pellets were calculated 
according to the diagnoses listed in Table 2. The reproducibility (REP) of the PCK is defined as the percentage of concordant results. CSF, 
cerebrospinal fluid; WBC, white blood cells; TOX, Toxoplasrna gondii; EBV, Epstein-Barr virus; JCV, J C  polyoma virus. 
”Number of positive PCR/number of specimens analyzed. 
’Number of positive P C R  in the CSF supernatant/number of corresponding positive CSF pellets. 
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Patient 1 Patient 2 Patient 3 
2
JCV 
143 
- 
TQX 
134 
EBV 
209 
- 
- 
Figure 1 PCK analysis of cerebrospinal fluid. Representative CSF results arc shown for patients with PML (Paticnt 2 ) .  
TE (Patient 2) and PCL (Paticnt 3).  The P C R  was analvzed on 2.2% agarose electrophoresis gels stained with ethidiuni 
broniide. The respective aniplicons of JC virus (JCV), X~xoplasriril gondii (TOX) and Epstein-Barr virus (EBV) arc indicated 
(arrows). The external controls consisted of peripheral blood leukocyte (PBL) DNA, high and low positive controls as 
defined for each target in the methods section, and water. The standard diagnostic consists of duplicates of the paticnt 
specimen. flanked by water as negative controls, and the patient specimen spiked with the target as internal amplification 
control. 
Study In 21 of thew, '1 histologic diagnosis had been 
made All of thete CSF sanipleu had been centrifuged 
~ n d  the 5upernatants stored a t  -20°C As shown in 
Table 4, the tenwivities of TOX, JCV m d  EBV P C R  
detection were found to be 33%, 50% and 66%. 
wherea\ n o  false positives were observed (specificity of 
1 OO%I) 
DISCUSSION 
HIV-1-infected patients s ~ ~ - c  prone to nuriieroiis neuro- 
logic complications. sonie of which can be defined by 
CT o r  MRI scans as FBLs. I n  the present study, \ye 
prospectively evaluated the diagnostic role of CSF PCR 
for TOX, EBV 2nd JCV in 26 HIV-1 -infected patients 
presenting with focal neurologic signs and symptoms. 
Not unexpectedly, the causes of the clinical conditions 
were niultiple, eventually including five patients with- 
out radiologic evidence ofFBLs as well as eight patients 
with FBLs (38%), but suffering from conditionu other 
than TE, I'ML and PCL (Table 2). I n  contrast. the 
retrospective analysis was restricted to 27 additional 
HIV-1-infected patients with TE, PCL and PML froin 
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whom stored CSF supernatants were available from the 
Swiss HIV-1 Cohort Study (Table 4). 
Our retrospective analysis of these 27 stored CSF 
supernatants revealed that nested P C R  is a highly 
specific diagnostic tool for TE, PML and PCL (Table 
4). However, the low sensitivity of TOX P C R  limits 
its diagnostic application in the routine clinical situation. 
This is somewhat surprising in view of the fact that by 
targeting the 35-fold repeated B1 gene and with a 
detection threshold of five target copies, TOX P C R  
should theoretically detect less than one protozoon. 
Thus, the low clinical sensitivity of 33% was probably 
not due to lack of sensitivity in the PCR,  but to 
the real absence of the pathogen in the CSF super- 
natant. 
Recent studies on JCV detection by P C R  have 
explored the possibilities of increasing the sensitivity by 
repeated CSF sampling and by improving the DNA 
extraction [13]. For the prospective part of the study, 
we adopted the following strategy: (1) the sample 
preparation included both protease digestion and 
non-phenolic DNA extraction on spin columns to 
remove potential inhibitors; (2) the sensitivity of target 
amplification was monitored in parallel with a ‘spiked’ 
patient specimen; (3) the effect of prior CSF centri- 
fugation on P C R  sensitivity was studied; and (4) plasma 
and Wl3C preparations were analyzed in parallel 
to examine their diagnostic relevance. This protocol 
allowed the P C R  detection of JCV and TOX in CSF 
pellets of HIV-1 patients with TE and PML with a 
sensitivity and specificity of 80% and 100%, respec- 
tively. Moreover, a high reproducibility (297%) of the 
PCR results was observed. At this level, TOX and JCV 
P C R  became valuable diagnostic tools in the clinical 
routine situation, especially in view of the diverse 
differential diagnoses encountered prospectively. The 
false-negative TOX P C R  result in our study was 
obtained from a specimen sampled only 3 weeks after 
initiation of antitoxoplasma therapy. This has also 
been observed by other authors [10,20], explaining a 
sensitivity of 0% in a recent series of five TE cases using 
heat-denatured CSF directly in the P C R  reaction [ l l ] .  
Of  particular clinical importance is our observation 
that EBV P C R  was not a specific marker for PCL in 
the HIV-1 -infected patients. EBV signals were found 
in the prospectively studied cases with other etiologies, 
both with and without FBLs (histologically confirmed 
for TE and PML). Because the: plasma was negative, 
even when the WBCs were positive for EBV (Table 3) ,  
it seems likely that the positive EBV signals in the CSF 
preparations of non-PCL cases reflect latent virus in 
intrathecal B-cells rather than in tumor cells. Other 
authors have also detected EBV signals in the CSF 
in the absence of FBLs [9,14]. Although we cannot 
exclude the possibility that microlymphomas may have 
been present in some of the patients, the acute clinical 
and radiologic findings correlated better with the histo- 
logically documented PML and TE lesions. Moreover, 
the EBV PCR-positive cases of TE, cytomegalovirus 
encephalitis and neuroborreliosis represent situations in 
which a decision to use specific antimicrobial treatment 
is clearly better than irradiation. 
We observed a higher specificity of EBV P C R  in 
the CSF supernatants, consistent with the results of 
the retrospective analysis (Table 4), but at the cost of 
sensitivity. However, analysis of CSF supernatants alone 
cannot be recommended, as our systematic analysis 
revealed a failure to detect two of three PCL cases in 
the prospective study group. Because immunocom- 
promised HIV-1-infected patients possibly show higher 
EBV viral load compared to immunocompetent in- 
dividuals, quantification of the EBV viral load in the 
CSF may improve the diagnostic value of EBV P C R  
for AIDS-associated PCL in the future. 
P C R  on plasma and WBC preparations was not 
diagnostically helpful, because of a low sensitivity 
for TOX and JCV In only one case of TE was TOX 
detected in the WBC preparation, suggesting dissemi- 
nated infection. This is in contrast to the results of 
Dupouy-Camet et a1 [2], who reported the detection 
of TOX in the blood of nine of 14 AIDS patients with 
presumptive TE. However, Khalifa et a1 [21] detected 
parasitemia in only two of their 15 TE cases. A tech- 
nical failure in our series is unlikely, given the use of an 
amplification control of spiked targets as well as the 
target-independent amplification control using human 
TNF-a primers (see methods section). Moreover, EBV 
was detected in 16 of the 19 WBC preparations. With 
respect to JCV DNA, Dubois et al [22] reported the 
detection ofJCV in 25% of PBL preparations obtained 
from 157 HIV-1-infected patients. Further studies are 
required to determine the significance of this. 
In conclusion, the combined results of this study 
suggest that spinal taps should be performed before the 
start of antiprotozoal therapy [lo], and that centri- 
fugation-enriched CSF preparations should be used for 
improved sensitivity for TE and PML. In contrast, a 
negative EBV PCR result under these conditions has a 
high negative predictive value which helps to exclude 
PCL as a cause for FBLs, while a positive result should 
be interpreted with reservation. For PML in particular, 
an early diagnosis helps to avoid unnecessary anti- 
microbial treatment and seems to be a prerequisite 
for the development and evaluation of new thera- 
peutic strategies. Given the diverse etiologies of FBLs 
encountered in this study, the improved CSF analysis 
by P C R  will have an impact on the management of 
these patients. 
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